How is HRI helping?
HRI is conducting innovative research to develop new therapies for heart failure and heart attack.
Researchers from our Cardiovascular Regeneration group, led by Dr Carmine Gentile, are working on an alternative to heart transplants using 3D-printed ‘mini-hearts’. The new technology creates personalised ‘bio-inks’ made of a patient’s own cells. These bioprinted cells form a ‘patch’, like a band-aid, which can then be used to replace the damaged tissue cause by heart failure.
Our Fluxomics Centre, led by Dr Sergey Tumanov, is devoted to identifying and exploring the cellular changes that are unique to each individual’s cardiovascular disease – with the ultimate goal of personalised methods to prevent, detect, and treat cardiovascular diseases like heart attack.
Our Coronary Diseases Group is investigating whether the anti-inflammatory drug colchicine, which has already proved safe and effective for treating conditions like arthritis and gout, can be repurposed to protect against repeat heart attacks. A collaboration between the Coronary Disease Group and our Clinical Research Group has also discovered that the heart releases certain substances during a heart attack that can be detected i